# Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

> **NCT01122888** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Solid Neoplasm
- Recurrent Adult Brain Neoplasm

## Interventions

- **DRUG:** Cilengitide
- **OTHER:** Clinical Observation
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01122888
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2012-09
- **Final completion:** 2015-04
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01122888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01122888, "Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01122888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*